OPTIMIZERx Corp
NASDAQ:OPRX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
OPTIMIZERx Corp
NASDAQ:OPRX
|
US |
|
T
|
Tamilnadu Telecommunication Ltd
BSE:523419
|
IN |
|
Hi Sun Technology (China) Ltd
HKEX:818
|
HK |
OPTIMIZERx Corp
OptimizeRx Corp. is digital health company, engaging in the provision of digital health messaging via electronic health records, which serve as a direct channel for pharmaceutical companies to communicate with healthcare providers. The company is headquartered in Rochester, Michigan and currently employs 97 full-time employees. The company went IPO on 2005-05-18. The firm enables engagement between life sciences organizations, healthcare providers and patients. The company connects approximately 60% of United States healthcare providers and their patients through a technology platform embedded within its own point-of-care network. The firm principal solutions and applications include financial messaging, brand therapeutic support messaging, and brand support. Its financial messaging enables doctors and staffs to access a universe of sample voucher, co-pay coupons and other patient support option through their electronic medical records (EMR) and/or e-prescribe system. Its brand messaging service includes brands awareness message, reminder advertisement, therapeutic support and unbranded messages. Its brand support is focused on educating and working with pharmaceuticals manufacturer on identifying, formulation and implementing new eRx media strategy for promoting their solutions.
OptimizeRx Corp. is digital health company, engaging in the provision of digital health messaging via electronic health records, which serve as a direct channel for pharmaceutical companies to communicate with healthcare providers. The company is headquartered in Rochester, Michigan and currently employs 97 full-time employees. The company went IPO on 2005-05-18. The firm enables engagement between life sciences organizations, healthcare providers and patients. The company connects approximately 60% of United States healthcare providers and their patients through a technology platform embedded within its own point-of-care network. The firm principal solutions and applications include financial messaging, brand therapeutic support messaging, and brand support. Its financial messaging enables doctors and staffs to access a universe of sample voucher, co-pay coupons and other patient support option through their electronic medical records (EMR) and/or e-prescribe system. Its brand messaging service includes brands awareness message, reminder advertisement, therapeutic support and unbranded messages. Its brand support is focused on educating and working with pharmaceuticals manufacturer on identifying, formulation and implementing new eRx media strategy for promoting their solutions.
Results: Revenue was $32.2 million in Q4 and $109.4 million for fiscal 2025; adjusted EBITDA was $12.0 million in Q4 and $24.3 million for the year.
Guidance: 2026 outlook narrowed to revenue of $109 million–$114 million and adjusted EBITDA of $21 million–$25 million, with management taking a more conservative revenue view.
Demand Headwind: Management cited softer year-to-date contracted revenue driven by a market shift away from managed services (≈$9 million in 1H25) and a broader, temporary conservatism tied to most favored nation (MFN) pricing discussions.
Margins & Mix: Q4 gross margin jumped to 74.8% (from 68.1% prior-year quarter) due to favorable channel and specialty messaging mix; company expects mid-60% gross margins in 2026.
Cash & Capital: Cash and short-term investments rose to $23.4 million; operating cash flow was $18.7 million for 2025; Board authorized a $10 million share repurchase program while continuing to prioritize debt paydown (current debt $26.3 million).
AI Positioning: Management said OptimizeRx has seen minimal disruption from AI and expects AI-driven content efficiencies to redeploy client budgets toward execution and reach—potential tailwind for the company's offerings.
Recurring Revenue Push: Company is converting DAP agreements toward subscription: run-rate exiting the year was "pretty close to 10%," up from mid-single digits for the full year, and management wants to grow this to improve predictability.
